Study: NCT04663347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
Description: 21-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab and lenalidomide
Description: 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab and lenalidomide
Description: 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab and bendamustine
Description: 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin
Description: 21-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and oxaliplatin
Description: 28-day cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone
Description: 21-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab, ifosfamide, carboplatin, and etoposide phosphate
Description: 21-day cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until disease progression or unacceptable toxicity.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until disease progression or unacceptable toxicity.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Every week in cycle 1 and then every 8 weeks for a total of 2 years.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Every week in cycle 1-3 and then every 4 weeks for a total of 2 years.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until transplant or disease progression.